 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-renal failure-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of renal failure?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes WARFARIN increase or decrease the risk of renal failure?[0m
 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes WARFARIN increase or decrease the risk of renal failure?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does WARFARIN increase the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"warfarin"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: WARFARIN: warnings_and_cautions: Those at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustment to desired INR, and a shortest duration of therapy [0m
[31mappropriate for the clinical condition. However, maintenance of INR in the therapeutic range does not eliminate the risk of bleeding. Drugs, dietary changes, and other factors affect INR levels [0m
[31machieved with warfarin sodium therapy. Perform more frequent INR monitoring when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs [0m[31m . Instruct patients [0m
[31mabout prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [0m[31m . [0m[1;31m5.2[0m[31m Tissue Necrosis Warfarin sodium can cause necrosis and/or gangrene of skin and other tissues,[0m
[31mwhich is an uncommon but serious risk [0m[1;31m([0m[1;31m<[0m[1;31m0.1[0m[31m%[0m[1;31m)[0m[31m. WARFARIN: warnings_and_cautions: Necrosis may be associated with local thrombosis and usually appears within a few days of the start of warfarin sodium [0m
[31mtherapy. In severe cases of necrosis, treatment through debridement or amputation of the affected tissue, limb, breast, or penis has been reported. Careful clinical evaluation is required to determine[0m
[31mwhether necrosis is caused by an underlying disease. Although various treatments have been attempted, no treatment for necrosis has been considered uniformly effective. Discontinue warfarin sodium [0m
[31mtherapy if necrosis occurs. Consider alternative drugs if continued anticoagulation therapy is necessary. [0m[1;31m5.3[0m[31m Calciphylaxis Warfarin sodium can cause fatal and serious calciphylaxis or calcium uremic [0m
[31marteriolopathy, which has been reported in patients with and without end-stage renal disease. When calciphylaxis is diagnosed in these patients, discontinue warfarin sodium and treat calciphylaxis as [0m
[31mappropriate. Consider alternative anticoagulation therapy. [0m[1;31m5[0m[31m. WARFARIN: warnings_and_cautions: [0m[1;31m4[0m[31m Acute Kidney Injury In patients with altered glomerular integrity or with a history of kidney disease, [0m
[31macute kidney injury may occur with warfarin sodium, possibly in relation to episodes of excessive anticoagulation and hematuria [0m[31m . More frequent monitoring of anticoagulation is advised in patients [0m
[31mwith compromised renal function. [0m[1;31m5.5[0m[31m Systemic Atheroemboli and Cholesterol Microemboli Anticoagulation therapy with warfarin sodium may enhance the release of atheromatous plaque emboli. Systemic [0m
[31matheroemboli and cholesterol microemboli can present with a variety of signs and symptoms depending on the site of embolization. The most commonly involved visceral organs are the kidneys followed by [0m
[31mthe pancreas, spleen, and liver. Some cases have progressed to necrosis or death. A distinct syndrome resulting from microemboli to the feet is known as â€œpurple toes syndrome. WARFARIN: [0m
[31mwarnings_and_cautions: Discontinue warfarin sodium therapy if such phenomena are observed. Consider alternative drugs if continued anticoagulation therapy is necessary. [0m[1;31m5.6[0m[31m Limb Ischemia, Necrosis, [0m
[31mand Gangrene in Patients with HIT and HITTS Do not use warfarin sodium as initial therapy in patients with heparin-induced thrombocytopenia [0m[1;31m([0m[31mHIT[0m[1;31m)[0m[31m and with heparin-induced thrombocytopenia with [0m
[31mthrombosis syndrome [0m[1;31m([0m[31mHITTS[0m[1;31m)[0m[31m. Cases of limb ischemia, necrosis, and gangrene have occurred in patients with HIT and HITTS when heparin treatment was discontinued and warfarin therapy was started or [0m
[31mcontinued. In some patients, sequelae have included amputation of the involved area and/or death. Treatment with warfarin sodium may be considered after the platelet count has normalized. [0m[1;31m5.7[0m[31m Use in [0m
[31mPregnant Women with Mechanical Heart Valves Warfarin sodium can cause fetal harm when administered to a pregnant woman. WARFARIN: warnings_and_cautions: While warfarin sodium is contraindicated during[0m
[31mpregnancy, the potential benefits of using warfarin sodium may outweigh the risks for pregnant women with mechanical heart valves at high risk of thromboembolism. In those individual situations, the [0m
[31mdecision to initiate or continue warfarin sodium should be reviewed with the patient, taking into consideration the specific risks and benefits pertaining to the individual patientâ€™s medical [0m
[31msituation, as well as the most current medical guidelines. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations [0m[1;31m([0m[31mwarfarin embryopathy and [0m
[31mfetotoxicity[0m[1;31m)[0m[31m, fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this [0m
[31mdrug, the patient should be apprised of the potential hazard to a fetus [0m[31m . [0m[1;31m5[0m[31m. WARFARIN: warnings_and_cautions: [0m[1;31m8[0m[31m Other Clinical Settings with Increased Risks In the following clinical settings, the [0m
[31mrisks of warfarin sodium therapy may be increased: Moderate to severe hepatic impairment Infectious diseases or disturbances of intestinal flora [0m[1;31m([0m[31me.g., sprue, antibiotic therapy[0m[1;31m)[0m[31m Use of an indwelling [0m
[31mcatheter Severe to moderate hypertension Deficiency in protein C-mediated anticoagulant response: Warfarin sodium reduces the synthesis of the naturally occurring anticoagulants, protein C and protein[0m
[31mS. Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Concomitant anticoagulation therapy with [0m
[31mheparin for [0m[1;31m5[0m[31m to [0m[1;31m7[0m[31m days during initiation of therapy with warfarin sodium may minimize the incidence of tissue necrosis in these patients. WARFARIN: warnings_and_cautions: Eye surgery: In cataract [0m
[31msurgery, warfarin sodium use was associated with a significant increase in minor complications of sharp needle and local anesthesia block but not associated with potentially sight-threatening [0m
[31moperative hemorrhagic complications. As warfarin sodium cessation or reduction may lead to serious thromboembolic complications, the decision to discontinue warfarin sodium before a relatively less [0m
[31minvasive and complex eye surgery, such as lens surgery, should be based upon the risks of anticoagulant therapy weighed against the benefits. Polycythemia vera Vasculitis Diabetes mellitus [0m[1;31m5.9[0m[31m [0m
[31mEndogenous Factors Affecting INR The following factors may be responsible for increased INR response: diarrhea, hepatic disorders, poor nutritional state, steatorrhea, or vitamin K deficiency. The [0m
[31mfollowing factors may be responsible for decreased INR response: increased vitamin K intake or hereditary warfarin resistance.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: drug_interactions: , methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, [0m
[31mzileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, [0m
[31mcilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, fosamprenav WARFARIN: [0m
[31mdrug_interactions: ir, imatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, ranitidine, ranolazine, [0m
[31mritonavir, saquinavir, telithromycin, tipranavir, voriconazole, zileuton armodafinil, amprenavir, aprepitant, bosentan, carbamazepine, efavirenz, etravirine, modafinil, nafcillin, phenytoin, [0m
[31mpioglitazone, prednisone, rifampin, rufinamide [0m[1;31m7.3[0m[31m Drugs that Increase Bleeding Risk Examples of drugs known to increase the risk of bleeding are presented in Table [0m[1;31m3[0m[31m . WARFARIN: drug_interactions: [0m
[31mBecause bleeding risk is increased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin. WARFARIN: drug_interactions: Table [0m[1;31m3[0m[31m: Drugs [0m
[31mthat Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel,[0m
[31mdipyridamole, prasugrel, ticlopidine Non-steroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, [0m
[31moxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlaf WARFARIN: [0m
[31mdrug_interactions: axine, vilazodone [0m[1;31m7.4[0m[31m Antibiotics and Antifungals There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic [0m
[31mstudies have not shown consistent effects of these agents on plasma concentrations of warfarin. Closely monitor INR when starting or stopping any antibiotic or antifungal in patients taking warfarin. [0m
[1;31m7.5[0m[31m Botanical [0m[1;31m([0m[31mHerbal[0m[1;31m)[0m[31m Products and Foods More frequent INR monitoring should be performed when starting or stopping botanicals. Few adequate, well-controlled studies evaluating the potential for [0m
[31mmetabolic and/or pharmacologic interactions between botanicals and warfarin sodium exist. Due to a lack of manufacturing standardization with botanical medicinal preparations, the amount of active [0m
[31mingredients may vary. This could further confound the ability to assess potential interactions and effects on anticoagulation. Some botanicals may cause bleeding events when taken alone [0m[1;31m([0m[31me.g.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: use_in_specific_populations: [0m[1;31m8[0m[31m USE IN SPECIFIC POPULATIONS Pregnant women with mechanical heart valves: Warfarin sodium may cause fetal harm; however, the benefits may outweigh the [0m
[31mrisks. [0m[1;31m([0m[31m [0m[1;31m8.1[0m[31m [0m[1;31m)[0m[31m Lactation: Monitor breastfeeding infants for bruising or bleeding. [0m[1;31m([0m[31m [0m[1;31m8.2[0m[31m [0m[1;31m)[0m[31m Renal Impairment: Instruct patients with renal impairment to frequently monitor their INR. [0m[1;31m([0m[31m [0m[1;31m8.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m8.1[0m[31m [0m
[31mPregnancy Risk Summary Warfarin sodium is contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism, and for whom the [0m
[31mbenefits of warfarin sodium may outweigh the risks [0m[31m . Warfarin sodium can cause fetal harm. Exposure to warfarin during the first trimester of pregnancy caused a pattern of congenital malformations in[0m
[31mabout [0m[1;31m5[0m[31m% of exposed offspring. WARFARIN: use_in_specific_populations: Because these data were not collected in adequate and well-controlled studies, this incidence of major birth defects is not an [0m
[31madequate basis for comparison to the estimated incidences in the control group or the U.S. general population and may not reflect the incidences observed in practice. Consider the benefits and risks [0m
[31mof warfarin sodium and possible risks to the fetus when prescribing warfarin sodium to a pregnant woman. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of [0m
[31mmedications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth [0m
[31mdefects and miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m% to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m% to [0m[1;31m20[0m[31m%, respectively. Clinical Considerations Fetal/Neonatal Adverse Reactions In humans, warfarin crosses the [0m
[31mplacenta, and concentrations in fetal plasma approach the maternal values. WARFARIN: use_in_specific_populations: Exposure to warfarin during the first trimester of pregnancy caused a pattern of [0m
[31mcongenital malformations in about [0m[1;31m5[0m[31m% of exposed offspring. Warfarin embryopathy is characterized by nasal hypoplasia with or without stippled epiphyses [0m[1;31m([0m[31mchondrodysplasia punctata[0m[1;31m)[0m[31m and growth [0m
[31mretardation [0m[1;31m([0m[31mincluding low birth weight[0m[1;31m)[0m[31m. Central nervous system and eye abnormalities have also been reported, including dorsal midline dysplasia characterized by agenesis of the corpus callosum, [0m
[31mDandy-Walker malformation, midline cerebellar atrophy, and ventral midline dysplasia characterized by optic atrophy. Mental retardation, blindness, schizencephaly, microcephaly, hydrocephalus, and [0m
[31mother adverse pregnancy outcomes have been reported following warfarin exposure during the second and third trimesters of pregnancy [0m[31m . [0m[1;31m8[0m[31m.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: use_in_specific_populations: The developing hemostatic system in infants and children results in a changing physiology of thrombosis and response to anticoagulants. Dosing of [0m
[31mwarfarin in the pediatric population varies by patient age, with infants generally having the highest, and adolescents having the lowest milligram per kilogram dose requirements to maintain target [0m
[31mINRs. Because of changing warfarin requirements due to age, concomitant medications, diet, and existing medical condition, target INR ranges may be difficult to achieve and maintain in pediatric [0m
[31mpatients, and more frequent INR determinations are recommended. Bleeding rates varied by patient population and clinical care center in pediatric observational studies and patient registries. Infants [0m
[31mand children receiving vitamin K-supplemented nutrition, including infant formulas, may be resistant to warfarin therapy, while human milk-fed infants may be sensitive to warfarin therapy. [0m[1;31m8[0m[31m. [0m
[31mWARFARIN: use_in_specific_populations: [0m[1;31m5[0m[31m Geriatric Use Of the total number of patients receiving warfarin sodium in controlled clinical trials for which data were available for analysis, [0m[1;31m1885[0m[31m patients[0m
[1;31m([0m[1;31m24.4[0m[31m%[0m[1;31m)[0m[31m were [0m[1;31m65[0m[31m years and older, while [0m[1;31m185[0m[31m patients [0m[1;31m([0m[1;31m2.4[0m[31m%[0m[1;31m)[0m[31m were [0m[1;31m75[0m[31m years and older. No overall differences in effectiveness or safety were observed between these patients and younger patients, but [0m
[31mgreater sensitivity of some older individuals cannot be ruled out. Patients [0m[1;31m60[0m[31m years or older appear to exhibit greater than expected INR response to the anticoagulant effects of warfarin [0m[31m . Warfarin [0m
[31msodium is contraindicated in any unsupervised patient with senility. Conduct more frequent monitoring for bleeding with administration of warfarin sodium to elderly patients in any situation or with [0m
[31many physical condition where added risk of hemorrhage is present. WARFARIN: use_in_specific_populations: Consider lower initiation and maintenance doses of warfarin sodium in elderly patients [0m[31m . [0m[1;31m8.6[0m[31m [0m
[31mRenal Impairment Renal clearance is considered to be a minor determinant of anticoagulant response to warfarin. No dosage adjustment is necessary for patients with renal impairment. Instruct patients [0m
[31mwith renal impairment taking warfarin to monitor their INR more frequently [0m[31m . [0m[1;31m8.7[0m[31m Hepatic Impairment Hepatic impairment can potentiate the response to warfarin through impaired synthesis of clotting [0m
[31mfactors and decreased metabolism of warfarin. Conduct more frequent monitoring for bleeding when using warfarin sodium in these patients.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: adverse_reactions: [0m[1;31m6[0m[31m ADVERSE REACTIONS The following serious adverse reactions to warfarin sodium are discussed in greater detail in other sections of the labeling: Hemorrhage [0m[31m [0m
[31mTissue Necrosis [0m[31m Calciphylaxis [0m[31m Acute Kidney Injury [0m[31m Systemic Atheroemboli and Cholesterol Microemboli [0m[31m Limb Ischemia, Necrosis, and Gangrene in Patients with HIT and HITTS [0m[31m Other Clinical Settings [0m
[31mwith Increased Risks [0m[31m Other adverse reactions to warfarin sodium include: Immune system disorders: hypersensitivity/allergic reactions [0m[1;31m([0m[31mincluding urticaria and anaphylactic reactions[0m[1;31m)[0m[31m Vascular [0m
[31mdisorders: vasculitis Hepatobiliary disorders: hepatitis, elevated liver enzymes. Cholestatic hepatitis has been associated with concomitant administration of warfarin sodium and ticlopidine. [0m
[31mGastrointestinal disorders: nausea, vomiting, diarrhea, taste perversion, abdominal pain, flatulence, bloating Skin disorders: rash, dermatitis [0m[1;31m([0m[31mincluding bullous eruptions[0m[1;31m)[0m[31m, pruritus, alopecia [0m
[31mRespiratory disorders: tracheal or tracheobronchial calcification General disorders: chills Most common adverse reactions to warfarin sodium are fatal and nonfatal hemorrhage from any tissue or organ.[0m
[31mWARFARIN: adverse_reactions: [0m[1;31m([0m[31m [0m[1;31m6[0m[31m [0m[1;31m)[0m[31m To report SUSPECTED ADVERSE REACTIONS, contact Teva at [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m838[0m[31m-[0m[1;31m2872[0m[31m or FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m or www.fda.gov/medwatch.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: dosage_and_administration: Table [0m[1;31m1[0m[31m: Three Ranges of Expected Maintenance Warfarin Sodium Tablets Daily Doses Based on CYP2C9 and VKORC1 Genotypes â€  VKORC1 CYP2C9 *[0m[1;31m1[0m[31m/*[0m[1;31m1[0m[31m *[0m[1;31m1[0m[31m/*[0m[1;31m2[0m[31m *[0m[1;31m1[0m[31m/*[0m[1;31m3[0m[31m [0m
[31m*[0m[1;31m2[0m[31m/*[0m[1;31m2[0m[31m *[0m[1;31m2[0m[31m/*[0m[1;31m3[0m[31m *[0m[1;31m3[0m[31m/*[0m[1;31m3[0m[31m GG [0m[1;31m5[0m[31m to [0m[1;31m7[0m[31m mg [0m[1;31m5[0m[31m to [0m[1;31m7[0m[31m mg [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m mg [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m mg [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m mg [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m mg AG [0m[1;31m5[0m[31m to [0m[1;31m7[0m[31m mg [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m mg [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m mg [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m mg [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m mg [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m mg AA [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m mg [0m[1;31m3[0m[31m to [0m[1;31m4[0m[31m mg [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m mg [0m[1;31m0.5[0m[31m to [0m[1;31m2[0m[31m mg [0m[1;31m0.5[0m
[31mto [0m[1;31m2[0m[31m mg [0m[1;31m0[0m[31m. WARFARIN: dosage_and_administration: [0m[1;31m5[0m[31m to [0m[1;31m2[0m[31m mg â€  Ranges are derived from multiple published clinical studies. VKORC1âˆ’1639G > A [0m[1;31m([0m[31mrs9923231[0m[1;31m)[0m[31m variant is used in this table. Other co-inherited [0m
[31mVKORC1 variants may also be important determinants of warfarin dose. [0m[1;31m2.4[0m[31m Monitoring to Achieve Optimal Anticoagulation Warfarin sodium tablets have a narrow therapeutic range [0m[1;31m([0m[31mindex[0m[1;31m)[0m[31m, and their action[0m
[31mmay be affected by factors such as other drugs and dietary vitamin K. Therefore, anticoagulation must be carefully monitored during warfarin sodium tablets therapy. Determine the INR daily after the [0m
[31madministration of the initial dose until INR results stabilize in the therapeutic range. After stabilization, maintain dosing within the therapeutic range by performing periodic INRs. The frequency of[0m
[31mperforming INR should be based on the clinical situation but generally acceptable intervals for INR determinations are [0m[1;31m1[0m[31m to [0m[1;31m4[0m[31m weeks. WARFARIN: dosage_and_administration: Perform additional INR tests [0m
[31mwhen other warfarin products are interchanged with warfarin sodium tablets, as well as whenever other medications are initiated, discontinued, or taken irregularly. Heparin, a common concomitant drug,[0m
[31mincreases the INR [0m[31m . Determinations of whole blood clotting and bleeding times are not effective measures for monitoring of warfarin sodium tablets therapy. [0m[1;31m2.5[0m[31m Renal Impairment No dosage adjustment [0m
[31mis necessary for patients with renal failure. Monitor INR more frequently in patients with compromised renal function to maintain INR within the therapeutic range [0m[31m. [0m[1;31m2.6[0m[31m Missed Dose The anticoagulant [0m
[31meffect of warfarin sodium tablets persists beyond [0m[1;31m24[0m[31m hours. WARFARIN: dosage_and_administration: If a patient misses a dose of warfarin sodium tablets at the intended time of day, the patient should [0m
[31mtake the dose as soon as possible on the same day. The patient should not double the dose the next day to make up for a missed dose. [0m[1;31m2.7[0m[31m Treatment During Dentistry and Surgery Some dental or surgical [0m
[31mprocedures may necessitate the interruption or change in the dose of warfarin sodium tablets therapy. Consider the benefits and risks when discontinuing warfarin sodium tablets even for a short period[0m
[31mof time. Determine the INR immediately prior to any dental or surgical procedure. In patients undergoing minimally invasive procedures who must be anticoagulated prior to, during, or immediately [0m
[31mfollowing these procedures, adjusting the dosage of warfarin sodium tablets to maintain the INR at the low end of the therapeutic range may safely allow for continued anticoagulation. [0m[1;31m2[0m[31m. WARFARIN: [0m
[31mdosage_and_administration: [0m[1;31m8[0m[31m Conversion From Other Anticoagulants Heparin Since the full anticoagulant effect of warfarin sodium tablets is not achieved for several days, heparin is preferred for [0m
[31minitial rapid anticoagulation. During initial therapy with warfarin sodium tablets, the interference with heparin anticoagulation is of minimal clinical significance. Conversion to warfarin sodium [0m
[31mtablets may begin concomitantly with heparin therapy or may be delayed [0m[1;31m3[0m[31m to [0m[1;31m6[0m[31m days. To ensure therapeutic anticoagulation, continue full dose heparin therapy and overlap warfarin sodium tablets [0m
[31mtherapy with heparin for [0m[1;31m4[0m[31m to [0m[1;31m5[0m[31m days and until warfarin sodium tablets has produced the desired therapeutic response as determined by INR, at which point heparin may be discontinued.         [0m
[31mSOURCE:WARFARIN label[0m


[31mCONTENT: WARFARIN: spl_medguide_table: Your healthcare provider may need to check you. <[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule [0m
[31mRrule"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>What should I avoid while taking warfarin sodium tablets<content [0m[31mstyleCode[0m[31m=[0m[31m"italics"[0m[31m>?<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mcontent[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item>Do not do [0m
[31many activity or sport that may cause a serious injury.<[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>What are the possible [0m
[31mside effects of warfarin sodium tablets? WARFARIN: spl_medguide_table: content><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Warfarin sodium tablets may cause serious side effects, including: [0m
[31m<[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><list [0m[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item>See &#x201C;<content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>What is the most important information I should know about warfarin sodium [0m
[31mtablets?<[0m[31m/[0m[31mcontent[0m[31m>&#x201D; <[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Death of skin tissue [0m[1;31m([0m[31mskin necrosis or gangrene[0m[1;31m)[0m[31m.<[0m[31m/[0m[31mcontent[0m[31m> This can happen soon after starting warfarin sodium tablets. It happens [0m
[31mbecause blood clots form and block blood flow to an area of your body. Call your healthcare provider right away if you have pain, color, or temperature change to any area of your body. You may need [0m
[31mmedical care right away to prevent death or loss [0m[1;31m([0m[31mamputation[0m[1;31m)[0m[31m of your affected body part. <[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Kidney problems. WARFARIN: spl_medguide_table: <[0m[31m/[0m[31mcontent[0m[31m>Kidney injury [0m
[31mmay happen in people who take warfarin sodium tablets. Tell your healthcare provider right away if you develop blood in your urine. Your healthcare provider may do tests more often during treatment [0m
[31mwith warfarin sodium tablets to check for bleeding if you already have kidney problems. <[0m[31m/[0m[31mitem[0m[31m><item><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>&#x201C;Purple toes syndrome.&#x201D;<[0m[31m/[0m[31mcontent[0m[31m> Call your healthcare [0m
[31mprovider right away if you have pain in your toes and they look purple in color or dark in color. <[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><paragraph>These are not all of the side effects of warfarin sodium tablets. For more [0m
[31minformation, ask your healthcare provider or pharmacist. <[0m[31m/[0m[31mparagraph[0m[31m><paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at [0m[1;31m1[0m[31m-[0m[1;31m800[0m[31m-FDA-[0m[1;31m1088[0m[31m. WARFARIN: [0m
[31mspl_medguide_table: paragraph><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>How should I store warfarin sodium tablets?<[0m[31m/[0m[31mcontent[0m[31m><list [0m
[31mlistType[0m[31m=[0m[31m"unordered"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m"Disk"[0m[31m><item>Store warfarin sodium tablets at [0m[1;31m68[0m[31m&#xB0; to [0m[1;31m77[0m[31m&#xB0;F [0m[1;31m([0m[1;31m20[0m[31m&#xB0; to [0m[1;31m25[0m[31m&#xB0;C[0m[1;31m)[0m[31m. <[0m[31m/[0m[31mitem[0m[31m><item>Keep warfarin sodium tablets in a tightly closed container. [0m
[31m<[0m[31m/[0m[31mitem[0m[31m><item>Keep warfarin sodium tablets out of the light.<[0m[31m/[0m[31mitem[0m[31m><item>Follow your healthcare provider or pharmacist instructions about the right way to throw away outdated or unused warfarin sodium [0m
[31mtablets. <[0m[31m/[0m[31mitem[0m[31m><item>Females who are pregnant should not handle crushed or broken warfarin sodium tablets. WARFARIN: spl_medguide_table: <[0m[31m/[0m[31mitem[0m[31m><[0m[31m/[0m[31mlist[0m[31m><paragraph><content [0m[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>Keep [0m
[31mwarfarin sodium tablets and all medicines out of the reach of children. <[0m[31m/[0m[31mcontent[0m[31m><[0m[31m/[0m[31mparagraph[0m[31m><[0m[31m/[0m[31mtd[0m[31m><[0m[31m/[0m[31mtr[0m[31m><tr><td [0m[31mvalign[0m[31m=[0m[31m"top"[0m[31m [0m[31mcolspan[0m[31m=[0m[31m"2"[0m[31m [0m[31mstyleCode[0m[31m=[0m[31m" Botrule Toprule Lrule Rrule"[0m[31m><content [0m
[31mstyleCode[0m[31m=[0m[31m"bold"[0m[31m>General information about the safe and effective use of warfarin sodium tablets.<[0m[31m/[0m[31mcontent[0m[31m><paragraph[0m[1;31m>[0m[31mMedicines are sometimes prescribed for purposes other than those listed in a [0m
[31mMedication Guide. Do not use warfarin sodium tablets for a condition for which they were not prescribed. Do not give warfarin sodium tablets to other people, even if they have the same symptoms that [0m
[31myou have. They may harm them. You can ask your healthcare provider or pharmacist for information about warfarin sodium tablets that is written for health professionals.         [0m
[31mSOURCE:WARFARIN label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m
[32mANSWER: Warfarin can increase the risk of acute kidney injury, particularly in patients with altered glomerular integrity or with a history of kidney disease. This may occur in relation to episodes of[0m
[32mexcessive anticoagulation and hematuria. Patients with compromised renal function are advised to monitor their INR more frequently.[0m

[32mSOURCE: WARFARIN label[0m
[32mEXTRACT_START_END: In patients with altered glomerular[0m[32m...[0m[32m with compromised renal function.[0m
*[1m([0morchestrator-renal failure-WARFARIN[1m)[0m [37m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mANSWER: Warfarin can increase the risk of acute kidney injury, particularly[0m
[34min patients with altered glomerular integrity or with a history of kidney disease. This may occur in relation to episodes of excessive anticoagulation and hematuria. Patients with compromised renal [0m
[34mfunction are advised to monitor their INR more frequently.[0m

[34mSOURCE: WARFARIN label[0m
[34mEXTRACT_START_END: In patients with altered glomerular[0m[34m...[0m[34m with compromised renal function.[0m
 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does WARFARIN increase or decrease the risk of renal failure?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I asked FDAHandler whether WARFARIN increases or decreases the risk of renal failure."[0m[32m,[0m
[32m      [0m[32m"FDAHandler provided information from the WARFARIN label indicating that Warfarin can increase the risk of acute kidney injury, especially in patients with altered glomerular integrity or with a[0m
[32mhistory of kidney disease. This is particularly associated with episodes of excessive anticoagulation and hematuria. Patients with compromised renal function are advised to monitor their INR more [0m
[32mfrequently."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"Warfarin can increase the risk of acute kidney injury, which is a form of renal failure. This risk is particularly noted in patients with altered glomerular integrity or with a history [0m
[32mof kidney disease, and during episodes of excessive anticoagulation and hematuria. Therefore, patients with compromised renal function should monitor their INR levels more frequently to mitigate this [0m
[32mrisk."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-renal failure-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does WARFARIN increase or decrease the risk of renal failure?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I asked FDAHandler whether WARFARIN increases or decreases the risk of renal failure."[0m[34m,[0m
[34m      [0m[34m"FDAHandler provided information from the WARFARIN label indicating that Warfarin can increase the risk of acute kidney injury, especially in patients with altered glomerular integrity or with a[0m
[34mhistory of kidney disease. This is particularly associated with episodes of excessive anticoagulation and hematuria. Patients with compromised renal function are advised to monitor their INR more [0m
[34mfrequently."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"Warfarin can increase the risk of acute kidney injury, which is a form of renal failure. This risk is particularly noted in patients with altered glomerular integrity or with a history [0m
[34mof kidney disease, and during episodes of excessive anticoagulation and hematuria. Therefore, patients with compromised renal function should monitor their INR levels more frequently to mitigate this [0m
[34mrisk."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does WARFARIN increase or decrease the risk of renal failure?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I asked FDAHandler whether WARFARIN increases or decreases the risk of renal failure.[0m
[1;31m2[0m[31m. FDAHandler provided information from the WARFARIN label indicating that Warfarin can increase the risk of acute kidney injury, especially in patients with altered glomerular integrity or with a [0m
[31mhistory of kidney disease. This is particularly associated with episodes of excessive anticoagulation and hematuria. Patients with compromised renal function are advised to monitor their INR more [0m
[31mfrequently.[0m
[31m        -----[0m
[31m        Final answer: Warfarin can increase the risk of acute kidney injury, which is a form of renal failure. This risk is particularly noted in patients with altered glomerular integrity or with a [0m
[31mhistory of kidney disease, and during episodes of excessive anticoagulation and hematuria. Therefore, patients with compromised renal function should monitor their INR levels more frequently to [0m
[31mmitigate this risk.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-renal failure-WARFARIN[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-renal failure-WARFARIN[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-renal failure-WARFARIN[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-renal failure-WARFARIN[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m

[32mWarfarin can increase the risk of acute kidney injury, which is a form of renal failure. This risk is particularly noted in patients with altered glomerular integrity or with a history of kidney [0m
[32mdisease, and during episodes of excessive anticoagulation and hematuria. Therefore, patients with compromised renal function should monitor their INR levels more frequently to mitigate this risk.[0m
